Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement
|Articles|July 31, 2018

Emerging Collaboration in EU Drug Pricing and Reimbursement Table 2

Advertisement
External Link - table2.pdf

Advertisement
Global

Related Content

Advertisement
Stock.Adobe.com Manufacturing

U.S. Rare Disease Biotech Investing Rises After FDA’s PRV Program Renewal: Report

ByNicholas Jacobus
August 11th 2026
Ron Lanton

Legal Risk in a Rumored AstraZeneca-BMS Deal: Q&A with Ron Lanton

ByNicholas Jacobus,Ron Lanton
August 6th 2026
A Phase 3 program demonstrated an acceptable safety profile for mFLUSIVA, with no new safety signals reported, consistent with previously reported studies of mFLUSIVA. Credit: Stock.Adobe.com/Leigh Prather.

FDA Approves Moderna's mRNA-Based Flu Vaccine

ByPharmaceutical Executive Editorial Staff
August 6th 2026
stock.adobe.com business deal

Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report

ByNicholas Jacobus
August 5th 2026
stock.adobe.com

CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China

ByNicholas Jacobus
August 5th 2026
Advertisement
Advertisement

Trending on PharmExec

1

M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership

2

Why Integrated GMP Operating Models Are Reshaping Outsourced Manufacturing

3

Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321

4

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

5

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us